| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.0099 | 0.8 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.018 | 0.8 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.8 |